From Seekingalpha · · 30s
AbCellera Presents at UBS Biopharma Conference
AbCellera CEO shares antibody tech advances at UBS Global Biopharma Conference 2026.
In brief
AbCellera CEO shares antibody tech advances at UBS Global Biopharma Conference 2026. AbCellera's CEO highlights antibody platform progress targeting GPCRs and ion channels at UBS conference. Originally reported by Seekingalpha.
AbCellera CEO
Carl L. Hansen, CEO, President & Chairperson of AbCellera Biologics Inc. (ABCL) presented at UBS Global Biopharma Conference 2026.
Antibody Platform Focus
AbCellera's 14-year platform targets GPCRs, ion channels, and T-cell engagers with best-in-world technology.
Biotech Business Model

Company initially served pharma clients before developing its own therapeutics including covid-19 treatments.
The essence
AbCellera's CEO highlights antibody platform progress targeting GPCRs and ion channels at UBS conference.
Read the TL;DR — this story on one card.